Current Edition


‘We have to make a stand’: Biotech leaders vow to break ties with Russia over Ukraine war

Hundreds of biotech leaders are pledging to stop working with Russian companies and to reject investment from Russian funds in response to the country’s invasion …

Continue Reading →
COVID-19 pill

In final analysis, Pfizer’s COVID-19 pill remains highly effective

Final study results show Pfizer’s experimental COVID-19 pill remained as effective as indicated by preliminary data last month, a major relief after promising data for …

Continue Reading →

Lilly deepens research ties in China with biotech deal

Lilly’s deal with Regor is another example of large pharmaceutical companies in the U.S. and Europe showing interest in Chinese biotechs for their research, rather …

Continue Reading →

Martin Shkreli’s former company to pay $40M in settlement over drug price hikes

Shkreli became a symbol of pharmaceutical greed after his company, formerly Turing Pharmaceuticals, bought Daraprim in 2015 and then raised the price to $750 a …

Continue Reading →

Neurocrine stocks up on a biotech’s psychiatric drugs

Neurocrine is perhaps best known for its work in movement disorders and women’s health, having developed approved medications for tardive dyskinesia and the pain associated …

Continue Reading →

Takeda wins US approval for new CMV treatment

Livtencity is part of the first wave of new products Takeda hopes will reposition the company as a top player in the pharmaceutical industry for …

Continue Reading →

Vertex aligns with another CRISPR gene editing startup

Mammoth’s evolution into a drugmaker appears to be paying off. Three years ago, the company formed with a plan to use CRISPR gene editing to …

Continue Reading →

AstraZeneca builds case for long-acting COVID-19 drug, but is it too late?

In some ways, AstraZeneca’s COVID-19 response has been as good as any in the biopharmaceutical industry. The British drugmaker licensed and developed an effective COVID-19 …

Continue Reading →
clinical trial

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Merck’s filing comes less than two weeks after the drugmaker showed molnupiravir lowered the risk of hospitalization or death by roughly 50% in a Phase …

Continue Reading →

Gene therapy developer gets chance at a comeback with Pfizer deal

Voyager’s first generation of gene therapies for ALS, Parkinson’s and Huntington’s disease, all now discontinued, relied on a direct infusion into brain tissue, an invasive …

Continue Reading →

Under pressure to share technology, Moderna to build vaccine factory in Africa

The announcement from Moderna comes amid criticism of the drugmaker, and other Western companies with authorized coronavirus vaccines, for not doing more to share their …

Continue Reading →

Insurers sue Merck for ‘monopolistic scheme’ to delay generics of blockbuster cholesterol drug

Insurers Centene and Humana have sued Merck & Co., alleging the drugmaker’s “monopolistic scheme” delayed generic versions of its blockbuster cholesterol drug Zetia from coming …

Continue Reading →

After coronavirus success, J&J hits setback with HIV vaccine

Before J&J become one of three companies that earned Food and Drug Administration approval for a coronavirus vaccine, the pharma was already a leader in …

Continue Reading →